Musk’s Neuralink Submits Brain Implant Patient Data to Journal

Neuralink Corp., the brain implant venture led by Elon Musk, has taken a significant step by submitting a scientific paper to a distinguished journal, detailing findings from its first human patients. This submission marks the company's inaugural foray into peer-reviewed publications featuring human data. The paper, which has been sent to the New England Journal of Medicine, outlines the outcomes of the initial three patients who received the Neuralink device, including critical safety information. Michael Lawton, the CEO of the Barrow Neurological Institute, where clinical trials are conducted, provided insights into this development during a recent brain-implant conference in New York, organized by Mount Sinai Health System. Neuralink stands among several organizations innovating in the field of brain-computer interfaces, which facilitate direct interaction between the brain and electronic devices. With over $1 billion raised and a valuation of $9 billion in its latest funding round, the company is keen to establish its credibility in the scientific community by publishing peer-reviewed human data—an essential milestone that will allow external researchers to assess the effectiveness of its devices. Lawton emphasized the notable influence of Musk's celebrity status on the field, which has attracted heightened interest and funding, propelling research and development across various companies. Despite the buzz, Neuralink has yet to release comprehensive details about the paper, and the company did not respond to inquiries for further comment. As of now, Neuralink has reported implanting its device in 12 individuals. The company's president, DJ Seo, mentioned plans to implant the device in a healthy participant by 2030. Historically, brain-computer interfaces have only been tested in patients with severe conditions. Lawton noted the company's cautious approach, focusing on patients with disabilities while expressing a broader vision to eventually cater to a wider audience. Neuralink aims to implant its chips in 20,000 individuals annually by 2031, with a target of generating at least $1 billion in yearly revenue. Beyond enabling computer control, the company is also developing chips aimed at restoring vision, interpreting speech from brain signals, and treating Parkinson's disease.